Advertisement

The effect of chronic kidney disease on lipid metabolism

  • Neris Dincer
  • Tuncay Dagel
  • Baris Afsar
  • Adrian Covic
  • Alberto Ortiz
  • Mehmet Kanbay
Nephrology - Review
  • 14 Downloads

Abstract

The major cause of death among chronic kidney disease patients is cardiovascular diseases. Cardiovascular and kidney disease are interrelated and increase the severity of each other. Dyslipidemia is one the major causes of cardiovascular disease among chronic kidney disease patients along with diabetes and hypertension. The relationship between dyslipidemia and chronic kidney disease is reciprocal. Dyslipidemia is known to be a risk factor for chronic kidney disease and chronic kidney disease causes major alterations on lipoprotein profile, defined as the “dyslipidemic profile” of chronic kidney disease patients. Increased triglyceride, very low density lipoprotein and oxidized low density lipoprotein as well as decreased high density lipoprotein and changes in the composition of lipoproteins contribute to the “dyslipidemic profile.” Treatment strategies targeting the “dyslipidemic profile” of chronic kidney disease could contribute to prevent cardiovascular diseases. Current therapy is based on the patient kidney function and consist mainly of statins. This review focuses on the effects of chronic kidney disease on the lipoprotein profile and how this may impact novel therapeutic approaches to cardiovascular risk.

Keywords

Chronic kidney disease PCSK9 Cholesterol Triglycerides HDL LDL 

Notes

Acknowledgements

MK gratefully acknowledges use of the services and facilities of the KoC University Research Center for Translational Medicine (KUTTAM), funded by the Republic of Turkey Ministry of Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Ministry of Development. AO was supported by FIS PI16/02057, ISCIII-RETIC REDinREN RD016/0009 FEDER funds, Sociedad Española de Nefrología, Fundacion Renal Iñigo Álvarez de Toledo (FRIAT), Comunidad de Madrid Biomedicina B2017/BMD-3686 CIFRA2-CM.

Funding

This study was not funded by any Grant.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Thomas B et al (2017) Global cardiovascular and renal outcomes of reduced GFR. J Am Soc Nephrol 28(7):2167–2179CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Zubovic SV et al (2016) Chronic kidney disease and lipid disorders. Med Arch 70(3):191–192CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Vanholder R et al (2016) Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diab Endocrinol 4(4):360–373CrossRefGoogle Scholar
  4. 4.
    Ortiz A et al (2014) Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383(9931):1831–1843CrossRefPubMedGoogle Scholar
  5. 5.
    Lamprea-Montealegre JA et al (2018) Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease. HeartGoogle Scholar
  6. 6.
    Bulbul MC et al (2018) Disorders of lipid metabolism in chronic kidney disease. Blood Purif 46(2):144–152CrossRefPubMedGoogle Scholar
  7. 7.
    Huang LH, Elvington A, Randolph GJ (2015) The role of the lymphatic system in cholesterol transport. Front Pharmacol 6:182PubMedPubMedCentralGoogle Scholar
  8. 8.
    Ossoli A, Pavanello C, Calabresi L (2016) High-density lipoprotein, lecithin: cholesterol acyltransferase, and atherosclerosis. Endocrinol Metab (Seoul) 31(2):223–229CrossRefGoogle Scholar
  9. 9.
    Miida T et al (2003) LCAT-dependent conversion of prebeta1-HDL into alpha-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol 14(3):732–738CrossRefPubMedGoogle Scholar
  10. 10.
    Speer T, Zewinger S, Fliser D (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrol Dial Transplant 28(10):2456–2463CrossRefPubMedGoogle Scholar
  11. 11.
    Florvall G, Basu S, Larsson A (2006) Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol A Biol Sci Med Sci 61(12):1262–1266CrossRefPubMedGoogle Scholar
  12. 12.
    Moradi H et al (2009) Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 153(2):77–85CrossRefPubMedGoogle Scholar
  13. 13.
    Moradi H et al (2010) Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease—response to antioxidant therapy. Clin Nephrol 74(4):273–281CrossRefPubMedGoogle Scholar
  14. 14.
    Goek ON et al (2012) Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrol Dial Transplant 27(7):2839–2847CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Zhan X et al (2018) Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. Lipids Health Dis 17(1):117CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lamprea-Montealegre JA et al (2014) Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study. Atherosclerosis 234(1):42–46CrossRefPubMedGoogle Scholar
  17. 17.
    Wolfrum C, Poy MN, Stoffel M (2005) Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 11(4):418–422CrossRefPubMedGoogle Scholar
  18. 18.
    Sorensen IM et al (2018) Apolipoprotein M in patients with chronic kidney disease. Atherosclerosis 275:304–311CrossRefPubMedGoogle Scholar
  19. 19.
    Gluba-Brzozka A et al (2017) Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients? Int Urol Nephrol 49(1):155–164CrossRefPubMedGoogle Scholar
  20. 20.
    Rysz-Gorzynska M, Gluba-Brzozka A, Banach M (2017) High-density lipoprotein and low-density lipoprotein subfractions in patients with chronic kidney disease. Curr Vasc Pharmacol 15(2):144–151CrossRefPubMedGoogle Scholar
  21. 21.
    Asztalos BF et al (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24(11):2181–2187CrossRefPubMedGoogle Scholar
  22. 22.
    Kwiterovich PO Jr (2000) The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86(12A):5L–10LCrossRefPubMedGoogle Scholar
  23. 23.
    Rubinow KB et al (2017) Kidney function is associated with an altered protein composition of high-density lipoprotein. Kidney Int 92(6):1526–1535CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Xiong X et al (2015) The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids Health Dis 14:127CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Riwanto M et al (2013) Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127(8):891–904CrossRefPubMedGoogle Scholar
  26. 26.
    Luo M et al (2017) ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. Sci Rep 7(1):2312CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Rocha M et al (2013) Association of serum retinol binding protein 4 with atherogenic dyslipidemia in morbid obese patients. PLoS ONE 8(11):e78670CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Axelsson J et al (2009) Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. Am J Nephrol 29(5):447–453CrossRefPubMedGoogle Scholar
  29. 29.
    Wang K et al (2018) Alteration of HDL Protein Composition with Hemodialysis Initiation. Clin J Am Soc Nephrol 13(8):1225–1233Google Scholar
  30. 30.
    Sutter I et al (2015) Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis 241(2):539–546CrossRefPubMedGoogle Scholar
  31. 31.
    Maeba R et al (2018) Association of cholesterol efflux capacity with plasmalogen levels of high-density lipoprotein: a cross-sectional study in chronic kidney disease patients. Atherosclerosis 270:102–109CrossRefPubMedGoogle Scholar
  32. 32.
    Levkau B (2015) HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications. Front Pharmacol 6:243CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nofer JR et al (2004) HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113(4):569–581CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Prufer N, Kleuser B, van der Giet M (2015) The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality. Biol Chem 396(6–7):573–583PubMedGoogle Scholar
  35. 35.
    Kimura T et al (2006) Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 281(49):37457–37467CrossRefPubMedGoogle Scholar
  36. 36.
    Sattler K, Levkau B (2009) Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 82(2):201–211CrossRefPubMedGoogle Scholar
  37. 37.
    Brinck JW et al (2018) High-density lipoprotein from end-stage renal disease patients exhibits superior cardioprotection and increase in sphingosine-1-phosphate. Eur J Clin Invest 48(2):e12866CrossRefGoogle Scholar
  38. 38.
    Vaziri ND, Liang K, Parks JS (2001) Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 59(6):2192–2196CrossRefGoogle Scholar
  39. 39.
    Calabresi L et al (2015) Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med 277(5):552–561CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Miljkovic M et al (2018) Association of dyslipidemia, oxidative stress, and inflammation with redox status in VLDL, LDL, and HDL lipoproteins in patients with renal disease. Angiology 69(10):861–870CrossRefPubMedGoogle Scholar
  41. 41.
  42. 42.
    Chistiakov DA et al (2017) Paraoxonase and atherosclerosis-related cardiovascular diseases. Biochimie 132:19–27CrossRefPubMedGoogle Scholar
  43. 43.
    Umemoto T et al (2013) Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 112(10):1345–1354CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Vaziri ND et al (2011) Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc 103(6):524–533CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Weichhart T et al (2012) Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 23(5):934–947CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Tolle M et al (2012) High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94(1):154–162CrossRefPubMedGoogle Scholar
  47. 47.
    Mao JY et al (2017) Serum amyloid A enrichment impairs the anti-inflammatory ability of HDL from diabetic nephropathy patients. J Diabetes Complications 31(10):1538–1543CrossRefPubMedGoogle Scholar
  48. 48.
    Heine GH et al (2012) Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 8(6):362–369CrossRefPubMedGoogle Scholar
  49. 49.
    Ganda A et al (2013) Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation 127(9):988–996CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Rogacev KS et al (2014) Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14 + + CD16 + monocyte counts that predict cardiovascular events in chronic kidney disease. Arterioscler Thromb Vasc Biol 34(9):2120–2127CrossRefPubMedGoogle Scholar
  51. 51.
    Zhang Y et al (2016) Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Ann Med 48(5):305–312CrossRefPubMedGoogle Scholar
  52. 52.
    Cetin MS et al (2016) Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart Lung Circ 25(11):1077–1086CrossRefPubMedGoogle Scholar
  53. 53.
    Kanbay M et al (2014) Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 46(8):1619–1625CrossRefPubMedGoogle Scholar
  54. 54.
    Speer T et al (2013) Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38(4):754–768CrossRefPubMedGoogle Scholar
  55. 55.
    Zewinger S et al (2017) Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur Heart J 38(20):1597–1607CrossRefPubMedGoogle Scholar
  56. 56.
    Shroff R et al (2014) HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype. J Am Soc Nephrol 25(11):2658–2668CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Musliner TA, Michenfelder HJ, Krauss RM (1988) Interactions of high density lipoproteins with very low and low density lipoproteins during lipolysis. J Lipid Res 29(3):349–361PubMedGoogle Scholar
  58. 58.
    Cwiklinska A et al (2018) Progression of chronic kidney disease affects HDL impact on lipoprotein lipase (LPL)-mediated VLDL lipolysis efficiency. Kidney Blood Press Res 43(3):970–978CrossRefPubMedGoogle Scholar
  59. 59.
    Zewinger S et al (2014) HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25(5):1073–1082CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Moradi H et al (2014) Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant 29(8):1554–1562CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Bowe B et al (2016) High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans. Clin J Am Soc Nephrol 11(10):1784–1793CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Chang TI et al. (2018) Inverse association between serum non-high-density lipoprotein cholesterol levels and mortality in patients undergoing incident hemodialysis. J Am Heart Assoc 7(12):e009096Google Scholar
  63. 63.
    Zewinger S et al (2015) Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J 36(43):3007–3016PubMedGoogle Scholar
  64. 64.
    Feingold KR, Grunfeld C (2000) Introduction to lipids and lipoproteins. In: De Groot LJ et al (eds) Endotext. MDText.com, Inc., South Dartmouth (MA)Google Scholar
  65. 65.
    Shiffman D et al (2017) LDL subfractions are associated with incident cardiovascular disease in the Malmo Prevention Project Study. Atherosclerosis 263:287–292CrossRefPubMedGoogle Scholar
  66. 66.
    Hager MR, Narla AD, Tannock LR (2017) Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord 18(1):29–40CrossRefPubMedGoogle Scholar
  67. 67.
    Chang KC et al (2015) Increased LDL electronegativity in chronic kidney disease disrupts calcium homeostasis resulting in cardiac dysfunction. J Mol Cell Cardiol 84:36–44CrossRefPubMedGoogle Scholar
  68. 68.
    Yang TC, Chang PY, Lu SC (2017) L5-LDL from ST-elevation myocardial infarction patients induces IL-1beta production via LOX-1 and NLRP3 inflammasome activation in macrophages. Am J Physiol Heart Circ Physiol 312(2):H265–H274CrossRefPubMedGoogle Scholar
  69. 69.
    Li D, Mehta JL (2005) Oxidized LDL, a critical factor in atherogenesis. Cardiovasc Res 68(3):353–354CrossRefPubMedGoogle Scholar
  70. 70.
    Napoli C et al (2000) Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J 14(13):1996–2007CrossRefPubMedGoogle Scholar
  71. 71.
    Weiner DE, Sarnak MJ (2004) Managing dyslipidemia in chronic kidney disease. J Gen Intern Med 19(10):1045–1052CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Tavridou A et al (2015) Association of plasma adiponectin and oxidized low-density lipoprotein with carotid intima-media thickness in diabetic nephropathy. J Diabetes Res 2015:507265CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Samouilidou EC et al (2012) Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Ren Fail 34(2):160–164CrossRefPubMedGoogle Scholar
  74. 74.
    Ribeiro S et al (2012) Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodial Int 16(4):481–490CrossRefPubMedGoogle Scholar
  75. 75.
    Anber V et al (1996) Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 124(2):261–271CrossRefPubMedGoogle Scholar
  76. 76.
    Mohty D et al (2008) Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 28(1):187–193CrossRefPubMedGoogle Scholar
  77. 77.
    Hoogeveen RC et al (2014) Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 34(5):1069–1077CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Ivanova EA et al (2017) Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid Med Cell Longev 2017:1273042CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Shen H et al (2016) Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients. BMC Nephrol 17(1):143CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Sonmez D et al (2014) Is there a relationship between small, dense LDL and lipoprotein–associated phospholipase A2 mass in dialysis patients? Clin Lab 60(9):1431–1437PubMedGoogle Scholar
  81. 81.
    Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43(9):1363–1379CrossRefPubMedGoogle Scholar
  82. 82.
    Sharma GS, Kumar T, Singh LR (2014) N-homocysteinylation induces different structural and functional consequences on acidic and basic proteins. PLoS ONE 9(12):e116386CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Ferretti G et al (2004) Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 92(2):351–360CrossRefPubMedGoogle Scholar
  84. 84.
    Ferretti G et al (2006) Homocysteinylation of low-density lipoproteins (LDL) from subjects with Type 1 diabetes: effect on oxidative damage of human endothelial cells. Diabet Med 23(7):808–813CrossRefPubMedGoogle Scholar
  85. 85.
    Zinellu A et al (2010) Increased low-density lipoprotein S-homocysteinylation in chronic kidney disease. Am J Nephrol 32(3):242–248CrossRefPubMedGoogle Scholar
  86. 86.
    Zinellu A et al (2012) LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. Eur J Pharm Sci 47(1):117–123CrossRefPubMedGoogle Scholar
  87. 87.
    De Nicola L et al (2015) Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: multicenter prospective study in Italy. Nutr Metab Cardiovasc Dis 25(8):756–762CrossRefPubMedGoogle Scholar
  88. 88.
    Visconti L et al (2016) Lipid disorders in patients with renal failure: role in cardiovascular events and progression of chronic kidney disease. J Clin Transl Endocrinol 6:8–14PubMedPubMedCentralGoogle Scholar
  89. 89.
    Bowden RG et al (2011) Reverse epidemiology of lipid-death associations in a cohort of end-stage renal disease patients. Nephron Clin Pract 119(3):c214–9CrossRefPubMedGoogle Scholar
  90. 90.
    Wanner C, Tonelli M, Improving global outcomes lipid guideline Development Work Group (2014) KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 85(6):1303–1309CrossRefPubMedGoogle Scholar
  91. 91.
    Phukan RR, Goswami RK (2017) Unusual dyslipidemia in patients with chronic kidney diseases. J Clin Diagn Res 11(1):BC01–BC04PubMedPubMedCentralGoogle Scholar
  92. 92.
    Shoji T et al (2001) Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis 38(4 Suppl 1):S30–S33CrossRefPubMedGoogle Scholar
  93. 93.
    Vaziri ND et al (2012) Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol 16(2):238–243CrossRefPubMedGoogle Scholar
  94. 94.
    Blaton V (2009) 8. dyslipidemia at chronic renal failure. EJIFCC 20(1):59–66PubMedPubMedCentralGoogle Scholar
  95. 95.
    Kaysen GA (2007) Hyperlipidemia in chronic kidney disease. Int J Artif Organs 30(11):987–992CrossRefPubMedGoogle Scholar
  96. 96.
    Xie X et al (2017) Association of very low-density lipoprotein cholesterol with all-cause and cardiovascular mortality in peritoneal dialysis. Kidney Blood Press Res 42(1):52–61CrossRefPubMedGoogle Scholar
  97. 97.
    Ooi EM et al (2011) Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. J Lipid Res 52(4):794–800CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Kohan AB (2015) Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 22(2):119–125CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Rocha NA et al (2017) ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. Curr Atheroscler Rep 19(12):62CrossRefPubMedGoogle Scholar
  100. 100.
    GA K (2006) Dyslipidemia in chronic kidney disease: causes and consequences. Kidney Int 70:S55–S58Google Scholar
  101. 101.
    Selmeci L et al (2005) Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: a simple, fast and inexpensive automated technique. Clin Chem Lab Med 43(3):294–297CrossRefPubMedGoogle Scholar
  102. 102.
    Skvarilova M et al (2005) Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149(1):83–87CrossRefPubMedGoogle Scholar
  103. 103.
    Vaziri ND (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290(2):F262–F272CrossRefPubMedGoogle Scholar
  104. 104.
    Mikolasevic I et al (2017) Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis 10:35–45CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Hirano T et al (2003) Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy: comparison with apoprotein CIII. Kidney Int 63(6):2171–2177CrossRefPubMedGoogle Scholar
  106. 106.
    Turak O et al (2016) The Role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict new cardiovascular events in essential hypertensive patients. J Clin Hypertens (Greenwich) 18(8):772–777CrossRefGoogle Scholar
  107. 107.
    Benjannet S et al (2004) NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279(47):48865–48875CrossRefPubMedGoogle Scholar
  108. 108.
    Abifadel M et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2):154–156CrossRefPubMedGoogle Scholar
  109. 109.
    Morena M et al (2017) Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: relationship with glomerular filtration rate and lipid metabolism. J Clin Lipidol 11(1):87–93CrossRefPubMedGoogle Scholar
  110. 110.
    McCormick SP (2004) Lipoprotein(a): biology and clinical importance. Clin Biochem Rev 25(1):69–80PubMedPubMedCentralGoogle Scholar
  111. 111.
    Hopewell JC, Haynes R, Baigent C (2018) The role of lipoprotein (a) in chronic kidney disease. J Lipid Res 59(4):577–585CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Lin J et al (2015) Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol 16:130CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Lin J et al (2014) Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS ONE 9(12):e114397CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Konishi H et al (2016) Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol 205:50–53CrossRefPubMedGoogle Scholar
  115. 115.
    Guerraty MA et al (2015) Relation of aortic valve calcium to chronic kidney disease (from the Chronic Renal Insufficiency Cohort Study). Am J Cardiol 115(9):1281–1286CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Toth PP et al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93(6):1397–1408CrossRefPubMedGoogle Scholar
  117. 117.
    Kanbay M et al (2009) Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. J Nephrol 22(5):598–609PubMedGoogle Scholar
  118. 118.
    Trialists CT (2016) C., et al., Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 4(10):829–839CrossRefGoogle Scholar
  119. 119.
    Ferro CJ et al. (2018) Lipid management in patients with chronic kidney disease. Nat Rev NephrolGoogle Scholar
  120. 120.
    Baigent C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192CrossRefPubMedPubMedCentralGoogle Scholar
  121. 121.
    Fukumoto Y (2018) Impact of statin-ezetimibe combination in chronic kidney disease. Int J Cardiol 268:36–37CrossRefPubMedGoogle Scholar
  122. 122.
    Yan YL et al (2015) High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open 5(5):e006886CrossRefPubMedPubMedCentralGoogle Scholar
  123. 123.
    Chung CM et al (2017) Effects of statin therapy on cerebrovascular and renal outcomes in patients with predialysis advanced chronic kidney disease and dyslipidemia. J Clin Lipidol 11(2):422–431 e2CrossRefPubMedGoogle Scholar
  124. 124.
    Walther CP et al (2018) Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant.  https://doi.org/10.1093/ndt/gfy237 CrossRefPubMedGoogle Scholar
  125. 125.
    Wanner C et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238–248CrossRefPubMedGoogle Scholar
  126. 126.
    Chan KE et al (2010) Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clin J Am Soc Nephrol 5(5):856–866CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Fellstrom B et al (2005) Effect of rosuvastatin on outcomes in chronic haemodialysis patients—design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 6(1):9CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    Athyros VG et al (2009) Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention. Curr Vasc Pharmacol 7(3):264–266CrossRefPubMedGoogle Scholar
  129. 129.
    Cho EY et al (2017) Efficacy of statin treatment in early-stage chronic kidney disease. PLoS ONE 12(1):e0170017CrossRefPubMedPubMedCentralGoogle Scholar
  130. 130.
    Scarpioni R et al (2012) Treatment of dyslipidemia in chronic kidney disease: effectiveness and safety of statins. World J Nephrol 1(6):184–194CrossRefPubMedPubMedCentralGoogle Scholar
  131. 131.
    Balk EM et al (2003) Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139(8):670–682CrossRefPubMedGoogle Scholar
  132. 132.
    Hottelart C et al (2002) Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 92(3):536–541CrossRefPubMedGoogle Scholar
  133. 133.
    McPherson R et al (2006) Canadian Cardiovascular Society position statement–recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22(11):913–927CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Jun M et al (2012) Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 60(20):2061–2071CrossRefPubMedGoogle Scholar
  135. 135.
    Weinstein DL et al (2013) A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease. Clin Ther 35(8):1186–1198CrossRefPubMedGoogle Scholar
  136. 136.
    Kasiske B et al (2004) Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4(Suppl 7):13–53CrossRefPubMedGoogle Scholar
  137. 137.
    Vanholder R et al. (2018) Deleting death and dialysis: conservative care of cardio-vascular risk and kidney function loss in chronic kidney disease (CKD). Toxins (Basel). 10(6):237CrossRefGoogle Scholar
  138. 138.
    Hassan KS et al (2010) Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren Fail 32(9):1031–1035CrossRefPubMedGoogle Scholar
  139. 139.
    Tannock L (2000) Dyslipidemia in chronic kidney disease. In: De Groot LJ et al (eds) Endotext. MDText.com, Inc., South Dartmouth (MA)Google Scholar
  140. 140.
    Jin Kang H et al (2013) Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease. Kidney Res Clin Pract 32(1):21–26CrossRefPubMedGoogle Scholar
  141. 141.
    Ix JH et al (2011) Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients. Am J Kidney Dis 57(6):963–965PubMedGoogle Scholar
  142. 142.
    Malhotra R et al (2018) The effect of extended release niacin on markers of mineral metabolism in CKD. Clin J Am Soc Nephrol 13(1):36–44CrossRefPubMedGoogle Scholar
  143. 143.
    Harper CR, Jacobson TA (2008) Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 51(25):2375–2384CrossRefPubMedGoogle Scholar
  144. 144.
    Kalil RS et al (2015) Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney Int 87(6):1250–1257CrossRefPubMedPubMedCentralGoogle Scholar
  145. 145.
    Stoekenbroek RM, Kastelein JJ, Huijgen R (2015) PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Med 13:258CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Zheng-Lin B, Ortiz A (2018) Lipid management in Chronic Kidney Disease: systematic review of PCSK9 targeting. Drugs 78(2):215–229CrossRefPubMedGoogle Scholar
  147. 147.
    Toth PP et al (2016) Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo. Lipids Health Dis 15:28CrossRefPubMedPubMedCentralGoogle Scholar
  148. 148.
    Mafham M, Haynes R (2018) PCSK9 inhibition: ready for prime time in CKD? Kidney Int 93(6):1267–1269CrossRefPubMedGoogle Scholar
  149. 149.
    Elewa U et al (2016) PCSK9 in diabetic kidney disease. Eur J Clin Invest 46(9):779–786CrossRefPubMedGoogle Scholar
  150. 150.
    Barcellos FC et al (2015) Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clin Kidney J 8(6):753–765CrossRefPubMedPubMedCentralGoogle Scholar
  151. 151.
    Miele EM et al (2017) High-density lipoprotein particle pattern and overall lipid responses to a short-term moderate-intensity aerobic exercise training intervention in patients with chronic kidney disease. Clin Kidney J 10(4):524–531CrossRefPubMedPubMedCentralGoogle Scholar
  152. 152.
    Afsar B et al (2014) An update on coronary artery disease and chronic kidney disease. Int J Nephrol 2014:767424CrossRefPubMedPubMedCentralGoogle Scholar
  153. 153.
    Shen H et al (2018) Effects of statin therapy on chronic kidney disease patients with coronary artery disease. Lipids Health Dis 17(1):84CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of MedicineKoc University School of MedicineIstanbulTurkey
  2. 2.Division of Nephrology, Department of MedicineKoc University School of MedicineIstanbulTurkey
  3. 3.Division of Nephrology, Department of MedicineSuleyman Demirel University School of MedicineIspartaTurkey
  4. 4.Nephrology Department, Dialysis and Renal Transplant Center, “Dr. C.I. Parhon” University Hospital“Grigore T. Popa’’ University of Medicine and PharmacyIasiRomania
  5. 5.Dialysis Unit, School of Medicine, IIS-Fundacion Jimenez DiazUniversidad Autónoma de MadridMadridSpain

Personalised recommendations